rfxcel Awarded ISO 9001:2015 Certification
rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.
The certifying organization used by rfxcel examined rfxcel’s commitment to customer service and requests, commitment to quality from upper management, and processes and procedures put in place to ensure the delivery of quality systems. rfxcel demonstrated its long-standing commitment to quality management and processes and was officially certified on November 4, 2018.
“This certification is a testament to rfxcel’s determination and commitment to continually improve as a business, provide our customers with uncompromising experiences, and drive a culture that produces high-quality products and services. Attaining this certification indicates the dedication rfxcel has taken in supporting our customers and exceeding their expectations. Quality is one of our strengths, and it is the reason we are the preferred partner for organizations globally.” – Amit Sewak, rfxcel, Director of Quality Management & Validation.
The scope of the certification included rfxcel’s flagship product rfxcel Traceability System for serialization (rTS). rTS is used by some of the world’s largest pharmaceutical manufacturers, wholesalers, distributors, and dispensers and is being adopted in other industries like Food and Beverage, Consumer Goods, and the Public Sector.
According to ISO, the 9001:2015 certification means that rfxcel demonstrated the seven following quality management principles for rTS:
• QMP 1 Customer Focus
• QMP 2 Leadership
• QMP 3 Engagement of People
• QMP 4 Process Approach
• QMP 5 Continual Improvement
• QMP 6 Evidence-Based Decision Making
• QMP 7 Relationship Management
“Very few if any of our competitors can claim to be ISO 9001:2015 certified. It is a testament to our role as a leader in our industry and our commitment to quality. This certification assures our customers that quality management practices are baked into our systems. Those quality practices and procedures are passed on to our customers through consistent products and services, which brings business benefits like a lower total cost of ownership and predictable outcomes.” – rfxcel, CEO Glenn Abood
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance